Department of Pharmaceutical Technology, Jadavpur University, Kolkata, India.
Drug Dev Ind Pharm. 2011 Sep;37(9):1016-25. doi: 10.3109/03639045.2011.557076. Epub 2011 Apr 20.
The objective of this study was to develop sustained release (SR) matrix tablets of metoprolol succinate (MS), by using different polymer combinations and fillers, to optimize by response surface methodology and to evaluate biopharmaceutical parameters of the optimized product. Matrix tablets of various combinations were prepared with cellulose-based polymers: hydroxy propyl methyl cellulose (HPMC) and ethyl cellulose (EC); and lactose and dibasic calcium phosphate dihydrate (DCP) as fillers. Study of pre-compression and post-compression parameters facilitated the screening of a formulation with best characteristics that underwent here optimization study by response surface methodology (Central Composite Design). The optimized tablet was subjected to further study like scanning electron microscopy, swelling study and in vivo study in rabbit model. Both in vitro and in vivo study revealed that combining of HPMC K100M (21.95%) with EC (8.85%), and use of DCP as filler sustained the action up to 12 h. The in vivo study of new SR tablets showed significant improvement in the oral bioavailability of MS in rabbits after a single oral dose of 25 mg. The delayed T(max) and lower C(max) indicated a slow and SR of MS from the optimized matrix tablets in comparison with the immediate release dosage form. The developed SR (MS) tablet of improved efficacy can perform therapeutically better than conventional tablet.
本研究旨在通过使用不同的聚合物组合和填充剂来开发琥珀酸美托洛尔(MS)的缓释(SR)基质片剂,通过响应面法进行优化,并评估优化产品的生物制药参数。使用基于纤维素的聚合物:羟丙基甲基纤维素(HPMC)和乙基纤维素(EC);以及乳糖和磷酸氢钙二水合物(DCP)作为填充剂,制备了各种组合的基质片剂。预压和后压参数的研究有助于筛选出具有最佳特性的配方,该配方通过响应面法(中心组合设计)进行了优化研究。对优化后的片剂进行了进一步研究,如扫描电子显微镜、溶胀研究和兔模型体内研究。体外和体内研究均表明,将 HPMC K100M(21.95%)与 EC(8.85%)结合使用,并使用 DCP 作为填充剂,可将作用持续 12 小时。新的 SR 片剂的体内研究表明,在单次口服 25mg 后,兔子中单剂量口服 MS 的生物利用度有了显著提高。与即刻释放剂型相比,延迟的 T(max)和较低的 C(max)表明 MS 从优化的基质片剂中缓慢释放和 SR。这种改善疗效的 SR(MS)片剂可在治疗上优于传统片剂。